ACE inhibitor reduces cardiovascular events by 22

Ivabradine reduces cardiovascular events in angina patients.

these substudy results in angina patients are concordant with the main findings of the BEAUTIfUL study as announced last year in Munich. ‘The sample size of angina patients in the substudy is relevant and the results are plausible’, he pointed out. The BEAUTIfUL trial (morbidity– mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfuncti...

The role of ACE inhibitor therapy in treating cardiovascular disease.

The first angiotensin-converting enzyme (ACE) inhibitors were introduced in 1981. They are used in the management of a variety of cardiovascular disorders and their role in hypertension, heart failure, managing asymptomatic and symptomatic left-ventricular dysfunction, post-myocardial infarction, stroke prevention, and diabetes is now well established. This is recognised in the National Service...

MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation.

AIM Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to block matrix metalloproteinase (MMP)-9 activity, which plays a role in atherogenesis. MMP-9 activity of macrophages is increased during foam cell formation. To investigate the contribution of ACEIs to foam cell formation, we studied the effects of an ACEI, imidaprilat, on THP-1 macrophages and the underlying molecular mecha...

Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.

The Heart Outcomes Prevention Evaluation (HOPE) study, an international randomized trial, was designed to evaluate the effects of the angiotensin-converting enzyme (ACE) inhibitor ramipril and vitamin E in patients at high risk for cardiovascular events. The study did not detect any cardiovascular benefit or harm using vitamin E. Results for the vitamin E arm are not discussed here. Of 9541 pat...

ACE inhibitor and swallowing reflex.